- Home
- OM vs AARD Comparison
OM vs AARD Comparison
Compare OM & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OM
- AARD
- Stock Information
- Founded
- OM 2003
- AARD 2017
- Country
- OM United States
- AARD United States
- Employees
- OM N/A
- AARD N/A
- Industry
- OM Biotechnology: Electromedical & Electrotherapeutic Apparatus
- AARD Biotechnology: Pharmaceutical Preparations
- Sector
- OM Health Care
- AARD Health Care
- Exchange
- OM Nasdaq
- AARD Nasdaq
- Market Cap
- OM 233.1M
- AARD 231.9M
- IPO Year
- OM 2020
- AARD 2025
- Fundamental
- Price
- OM $4.67
- AARD $9.91
- Analyst Decision
- OM Strong Buy
- AARD Strong Buy
- Analyst Count
- OM 3
- AARD 8
- Target Price
- OM $16.00
- AARD $30.63
- AVG Volume (30 Days)
- OM 618.9K
- AARD 162.6K
- Earning Date
- OM 11-10-2025
- AARD 11-13-2025
- Dividend Yield
- OM N/A
- AARD N/A
- EPS Growth
- OM N/A
- AARD N/A
- EPS
- OM N/A
- AARD N/A
- Revenue
- OM $120,069,000.00
- AARD N/A
- Revenue This Year
- OM $12.46
- AARD N/A
- Revenue Next Year
- OM $10.51
- AARD N/A
- P/E Ratio
- OM N/A
- AARD N/A
- Revenue Growth
- OM 4.65
- AARD N/A
- 52 Week Low
- OM $4.53
- AARD $4.88
- 52 Week High
- OM $25.35
- AARD $19.58
- Technical
- Relative Strength Index (RSI)
- OM 15.45
- AARD 39.27
- Support Level
- OM $11.41
- AARD $9.34
- Resistance Level
- OM $12.47
- AARD $11.51
- Average True Range (ATR)
- OM 0.82
- AARD 0.85
- MACD
- OM -0.97
- AARD -0.01
- Stochastic Oscillator
- OM 1.41
- AARD 20.39
About OM Outset Medical Inc.
Outset Medical Inc is a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis. The Company generates revenue from the sales of Tablo consoles and related consumables, including Tablo cartridges and accessories.
About AARD Aardvark Therapeutics Inc.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.